EUCTR2007-001219-44-IT进行中（未招募）不适用
Comparison of the efficacy and safety of a strategy of pre-hospital fibrinolytic treatment with tenecteplase and additional antiplatelet and antithrombin therapy followed by catheterisation within 6-24 hours or rescue coronary intervention versus a strategy of standard primary PCI in patients with acute myocardial infarction within 3 hours of onset of symptoms - STREAM
BOEHRINGER ING.0 个研究点目标入组 2,200 人开始时间: 2008年1月17日最近更新:
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 2,200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •-Age equal or greater than 18 years -Onset of symptoms < 3 hours prior to randomisation -12-lead ECG indicative of an acute STEMI (ST-elevation will be measured from the J point; scale: 1 mm per 0.1 mV): >= 2 mm ST-elevation across 2 contiguous precordial leads (V1-V6) or leads I and aVL for a minimum combined total of >= 4 mm ST-elevation or >= 3 mm ST-elevation in 2 contiguous inferior leads (II, III, aVF) for a minimum combined total of >= 6 mm ST-elevation -Informed consent received
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •-Expected performance of PCI < 60 minutes from diagnosis (qualifying ECG) or inability to arrive at the catheterisation laboratory within 3 hours -Previous CABG -Left bundle branch block or ventricular pacing -Patients with cardiogenic shock (Killip Class 4) -Patients with a body weight < 55 kg (known or estimated) -Uncontrolled hypertension, defined as a single blood pressure measurement >= 180/110 mm Hg (systolic BP >= 180 mm Hg and/or diastolic BP >= 110 mm Hg) prior to randomisation -Hospitalisation for cardiac reason within past 48 hours -Recent administration of any i.v. or s.c. anticoagulation within 12 hours including unfractionated heparin, enoxaparin and/or bivalirudin or current use of oral anti-coagulation (warfarin or coumadin) -Active bleeding or known bleeding disorder/diathesis -Any history of central nervous system damage (i.e. neoplasm, aneurysm, intracranial or spinal surgery) or recent trauma to the head or cranium (i.e. < 3 months) -Major surgery, biopsy of a parenchymal organ, or significant trauma within the past 2 months (this includes any trauma associated with the current myocardial infarction) -Any known history of haemorrhagic stroke, ischaemic stroke or transient ischaemic attack (TIA), or stroke of unknown origin -Prolonged or traumatic cardiopulmonary resuscitation (> 10 minutes) within the past 2 weeks -Known acute pericarditis and/or subacute bacterial endocarditis -Known acute pancreatitis or known severe hepatic dysfunction, including hepatic failure, cirrhosis, portal hypertension (oesophageal varices) and active hepatitis -Chronic dialysis or known renal insufficiency -Clinical diagnosis associated with increased risk of bleeding including known active peptic ulceration and/or neoplasm with increased bleeding risk -Arterial aneurysm and known arterial/venous malformation -Pregnancy or lactation or parturition within the previous 30 days; women of childbearing potential must have a negative urine pregnancy test, or use a medically accepted method of birth control -Previous enrolment in this study or treatment with an investigational drug or device under another study protocol in the past 7 days -Known hypersensitivity to tenecteplase, alteplase, acetylsalicylic acid, clopidogrel, enoxaparin, or to any of the excipients or to the contrast media used in angiography -Inability to follow the protocol and comply with follow-up requirements or any other reason that the investigator feels would place the patient at increased risk if the investigational therapy is initiated
研究者
相似试验
招募中
3 期
The effect of lidocaine spray and vapocolant spray in reducing the pain of venous catheterizatioReduce the pain of iv catheterization.IRCT20200707048047N3Islamic Azad University116
尚未招募
不适用
Comparison of effectiveness and safety according to the composition of bone graft material used with bioactive glass-ceramic cage (Novomax Fusion™) in cervical discectomy and fusion (ACDF): a prospective, controlled, single-blind, therapeutic exploratory studyKCT0007240The Catholic University of Korea, Eunpyeong St. Mary's Hospital45
招募中
4 期
Comparison of the efficacy and safety of tamsulosin OCAS with tamsulosin MR and placebo in improving lower urinary tract symptomsIRCT20100817004582N8rology Research Centre, Guilan University of Medical Sciences260
招募中
2 期
evaluation the effect of botulinum toxin type A for treating frown linesskin rejuvenation.IRCT20150101020514N8Imen vaccine alborz Company140
已完成
不适用
Comparative evaluation of the safety and efficacy of long term use of anti-cholinergic, Imidafenacin and Solifenacin, on overactive bladder: a prospective randomized trial.overactive bladderJPRN-UMIN000004354Department of Urology, Kanto Rosai Hospital60